This trial is evaluating whether JNJ-75229414 will improve 3 primary outcomes and 10 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Up to 28 days.
This trial requires 60 total participants across 2 different treatment groups
This trial involves 2 different treatments. JNJ-75229414 is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Jnj-75229414 exhibits anti-tumor properties in both mouse and human models of prostate cancer and extends its effect beyond apoptosis induction. Furthermore, it is cytotoxic even at low doses in vitro and enhances the effectiveness of ionizing radiation and docetaxel, suggesting that it could be used as a radiosensitizer." - Anonymous Online Contributor
"Our analysis confirms the existence of familial PCa and suggests that genetic predisposition to PCa may be associated with more aggressive disease. To our knowledge, this is the first report of a possible linkage between PCa and SPINK1 status." - Anonymous Online Contributor
"Taken together, our findings indicate that JNj-75229414 exerts its anti-tumor activity through a mechanism involving inhibition of p65 transcriptional activation, and suggest that this inhibitor might therefore be a promising therapeutic agent for prostate cancer treatment." - Anonymous Online Contributor
"Although present findings suggest that PDX1 expression may play a role in early carcinoma progression, further research is warranted to elucidate its potential as prognostic biomarker in prostate cancer." - Anonymous Online Contributor
"The mortality rate of prostate cancer in North America is higher than previously estimated. Although the age at diagnosis of prostate cancer is declining, the five-year survival rate remains stable. As the treatment options are improving, it will be important to continue to monitor the prognosis of prostate cancer." - Anonymous Online Contributor
"It is unclear if genetic factors are involved in prostate cancer development. In recent years, however, numerous gene alterations have been found in prostate cancer. It is also possible that environmental factors play an important role in prostate cancer development. These factors include diet, smoking, exposure to chemicals, infections, and type of sexual activity. The role of hormones such as estrogen, testosterone, and prolactin may be responsible for prostate cancer development. Dietary factors including intake of saturated fats, trans fatty acids, cholesterol, dietary fiber, and carbohydrate composition seem to be related to increased prostate cancer risk.\nStill, it remains unknown whether these changes occur before, during, or after prostate cancer development." - Anonymous Online Contributor
"A more accurate prediction of the likelihood of developing prostate cancer could be achieved if we use an increased number of biopsies taken over time. The best way to assess the probability of developing prostate cancer would seem to be to take multiple biopsies obtained at different times over the course of 5 years." - Anonymous Online Contributor
"Jnj-75229414 treatment appears to produce significant improvements in some patients' health status and quality of life, but it may also exacerbate symptoms in others. This reinforces the need for further evaluation before the use of this drug in clinical trials." - Anonymous Online Contributor
"Jnj-75229414 was found to be effective in treatment of more than half of patients with LUTS who were previously treated with either alpha-blockers or anticholinergics. It was generally well tolerated and resulted in significant improvements in LUTS symptoms." - Anonymous Online Contributor
"Estimates of the number of new cases of prostate cancer per year in the United States range from 4400 to 11,000 men. Recent findings suggests that prostate cancer incidence rates are unlikely to stabilize until incidence rates reach about 5000 cases per 100,000 man-years." - Anonymous Online Contributor